{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Salvage in Multiple Myeloma Patients: New Options Associated with Improved Outcomes - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"hEpJA581md\"><a href=\"https:\/\/themedicalxchange.com\/en\/2012\/01\/09\/53rd-american-society-of-hematology-ash-annual-mee\/\">Salvage in Multiple Myeloma Patients: New Options Associated with Improved Outcomes<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2012\/01\/09\/53rd-american-society-of-hematology-ash-annual-mee\/embed\/#?secret=hEpJA581md\" width=\"600\" height=\"338\" title=\"&#8220;Salvage in Multiple Myeloma Patients: New Options Associated with Improved Outcomes&#8221; &#8212; The Medical Xchange\" data-secret=\"hEpJA581md\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/01\/ASH_2011_Table_1_.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"San Diego - In patients with heavily pretreated multiple myeloma, clinically important outcomes are being achieved with new therapeutic agents. A number of phase II and III studies presented at the 2011 American Society of Hematology (ASH) meeting suggest that these novel drugs can revive the activity of previously employed agents, leading to clinically meaningful improvements in such outcomes as progression-free survival. The acceptable tolerability of these newer agents, many of which are administered orally, also suggests progress in extending survival in patients with refractory disease."}